Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma (PEXIUS)

This treatment has been approved for sale to the public.
Sponsor:
Information provided by (Responsible Party):
Celgene Corporation
ClinicalTrials.gov Identifier:
NCT01632826
First received: June 29, 2012
Last updated: April 4, 2014
Last verified: April 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This treatment has been approved for sale to the public.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given